Alrestatin

Alrestatin (AY-22284) is an aldose reductase inhibitor. Alrestatin reduces fructose levels in the uterine fluid of mice. Alrestatin interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin can be used in studies related to diabetes and reproductive diseases^[1][2]. In Vitro:Alrestatin (1-5 mg/mL; 15 min) dose-dependently inhibits basal and tyramine-stimulated ³H-norepinephrine release from rat splenic and pancreatic tissue samples in vitro^[1]. In Vivo:Alrestatin (0.75 mmol/kg; intravenous injection; single bolus) significantly enhances glucose-stimulated insulin secretion and improves glucose clearance in fasted, anesthetized non-diabetic male Sprague-Dawley rats, but exerts no effect on basal plasma glucose or insulin levels^[1].
Alrestatin (0.15 μg/μL; intrauterine infusion) significantly reduces fructose levels in mouse uterine fluid without altering glucose or sorbitol levels^[2].
Alrestatin (1.5 mmol/L; intrauterine injection) significantly reduces sperm capacitation rate and fertilization rate in mice, while co-administration of fructose or sorbitol reverses these effects^[2].